Soleno Therapeutics, Inc. SLNO
Set alert
53.01 USD 0.00 0.00%
At close · May 15
52.99 -0.02 -0.04%
After hours · May 15, 4:00 PM ET
52.98 Day range 53.01
29.43 52-week range 72.80
- YTD
- +14.49%
- 1 year
- -29.33%
- Open
- 52.99
- Prev close
- 53.01
- Mkt cap
- 2.76B
- Vol
- 4.97M
- Avg vol
- 1.75M
- EPS
- 1.77
- P/E
- 14.46
- Div yield
- 0.00%
More statistics
- Low
- 52.98
- High
- 53.01
- Beta
- -2.22
- Inst. own
- 111.53%
- Dividend
- 0.00
- Earnings
- Aug 5, 2026
6M chart
Events in this range
- Feb 25, 2026Earnings: 0.8; estimate 0.64; surprise 25%
- Mar 18, 2026Rating: Oppenheimer · Outperform → Outperform
- Apr 6, 2026Downgrade: Cantor Fitzgerald · Overweight → Neutral
- Apr 7, 2026Downgrade: Wolfe Research · Outperform → Peer Perform
- Apr 7, 2026Downgrade: TD Cowen · Buy → Hold
- Apr 8, 2026Downgrade: HC Wainwright & Co. · Buy → Neutral
- Apr 17, 2026Downgrade: Wells Fargo · Overweight → Equal-Weight
- May 7, 2026Earnings: 0.59; estimate 0.73; surprise -19.18%
Signals (16)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Apr 27, 2026 | 6 months ago |
| SMA: Bullish | Apr 6, 2026 | 7 months ago |
| RSI: Overbought | Apr 6, 2026 | 7 months ago |
| SMA: Bullish | Apr 2, 2026 | 7 months ago |
| MACD: Buy Signal | Apr 1, 2026 | 7 months ago |
| RSI: Oversold | Mar 27, 2026 | 7 months ago |
| RSI: Oversold | Mar 24, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 13, 2026 | 7 months ago |
| MACD: Buy Signal | Feb 20, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 12, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 2, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 30, 2026 | 9 months ago |
| RSI: Oversold | Jan 30, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 21, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 30, 2025 | 10 months ago |
| MACD: Buy Signal | Nov 25, 2025 | 11 months ago |
Key statistics
- Market cap
- 2.76B
- Enterprise value
- 2.63B
- Trailing P/E
- 27.09
- PEG ratio
- 0.02
- Price / sales
- 9.69
- Price / book
- 5.57
- Beta
- -2.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 33.70%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 22.86%
Analyst view
Price target (mean) —
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy5
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 5, 2026
Expected Aug 5, 2026. Consensus EPS estimate 0.68.
Financials — quick view
SLNO Revenue — quarterly 94.60M
SLNO Net income — quarterly 31.38M
SLNO EPS — quarterly 0.60
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 5, 2026 | Jun 30, 2026 | 0.91 | — | — | — |
| May 7, 2026 | Mar 31, 2026 | 0.73 | 0.59 | -0.14 | -19.18% |
| Feb 25, 2026 | Dec 31, 2025 | 0.64 | 0.80 | +0.16 | +25.00% |
| Nov 4, 2025 | Sep 30, 2025 | 0.0575 | 0.47 | +0.41 | +717.39% |
| Aug 6, 2025 | Jun 30, 2025 | -0.53 | -0.09 | +0.44 | +83.02% |
| May 7, 2025 | Mar 31, 2025 | -1.14 | -0.95 | +0.19 | +16.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 17, 2026 | Wells Fargo | down | Overweight | Equal-Weight |
| Apr 8, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
| Apr 7, 2026 | TD Cowen | down | Buy | Hold |
| Apr 7, 2026 | Wolfe Research | down | Outperform | Peer Perform |
| Apr 6, 2026 | Cantor Fitzgerald | down | Overweight | Neutral |
| Mar 18, 2026 | Oppenheimer | main | Outperform | Outperform |
About Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation. Established in 1999, the Redwood City, California-headquartered firm adopted its current name, Soleno Therapeutics, Inc., in May 2017, having previously operated as Capnia, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 115
- Website
- soleno.life
News
- Kuehn Law Encourages Investors of Soleno Therapeutics, Inc. to Contact Law Firm
- SLNO 8-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch Disruptions - Hagens Berman
- SOLENO DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNO
- BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
- SLNO DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Today's Lead Plaintiff Deadline in Securities Class Action
- Halper Sadeh LLC is Investigating Whether SLNO, APLS, HLX are Obtaining Fair Deals for their Shareholders
- Bronstein, Gewirtz & Grossman LLC Urges Soleno Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
- DEADLINE ALERT for EOSE, SLNO, and NKTR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
- Portnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. Investors
Your note
Sign in to keep a note on SLNO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANISH BHATNAGAR | Chief Executive Officer | Stock Award(Grant) | Jan 20, 2026 | 583,656 |
| FULK JENNIFER | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 1, 2026 | 39,200 |
| HIRANO PATRICIA C | Officer | Stock Award(Grant) | Jan 20, 2026 | 22,702 |
| HUANG MICHAEL F | Officer | Sale | Mar 26, 2026 | 39,823 |
| JOSHI MANHER | Officer | Stock Award(Grant) | Jan 20, 2026 | 20,171 |
| MACKANESS JAMES H | Chief Financial Officer | Stock Award(Grant) | Jan 20, 2026 | 131,763 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| HHG PLC | 13.62% | 7,099,328 | 0 | Mar 30, 2026 |
| FMR Inc | 11.11% | 5,788,410 | 0 | Mar 30, 2026 |
| Wellington Management Company LLP | 8.49% | 4,426,781 | 0 | Mar 30, 2026 |
| BlackRock Inc | 7.18% | 3,742,774 | 0 | Mar 30, 2026 |
| Vanguard Group Inc | 5.87% | 3,060,361 | 0 | Dec 30, 2025 |
| State Street Corp | 5.14% | 2,680,802 | 0 | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Health Care Inv | 5.78% | 3,012,287 | 0 | Mar 30, 2026 |
| Vanguard Total Stock Mkt Idx Inv | 3.00% | 1,562,890 | 0 | Apr 29, 2026 |
| Janus Henderson Global Life Sciences | 1.89% | 987,375 | 0 | Mar 30, 2026 |
| Janus Henderson Global Life Sciences D | 1.89% | 987,375 | 0 | Mar 30, 2026 |
| Janus Global Life Science AUSD | 1.75% | 910,949 | 0 | Mar 30, 2026 |
| International Biotechnology Ord | 1.24% | 648,529 | 0 | Apr 29, 2026 |